Deferoxamine

Known as: Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-, DFOM, Deferoximine 
An iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
BACKGROUND Cardiac complications secondary to iron overload are the leading cause of death in beta-thalassemia major… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated… (More)
  • table I
  • table II
  • table III
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND AND OBJECTIVES Seven Italian centers reported data on survival, causes of death and appearance of complications in… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
OBJECT Previous studies undertaken by the authors have indicated that iron accumulation and oxidative stress in the brain… (More)
Is this relevant?
Highly Cited
1994
Highly Cited
1994
BACKGROUND To determine whether deferoxamine prevents the complications of transfusional iron overload in thalassemia major, we… (More)
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Superoxide dismutase reduces injury in many disease processes, implicating superoxide anion radical (O2-.) as a toxic species in… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1986
Highly Cited
1986
Of 89 patients receiving nightly subcutaneous deferoxamine for transfusion-dependent thalassemia major or Diamond-Blackfan anemia… (More)
Is this relevant?
Highly Cited
1984
Highly Cited
1984
Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overload. This study demonstrates… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?